We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

SD BIOSENSOR

SD BIOSENSOR develops immunological and molecular diagnostics and blood glucose self-monitoring systems, glycated hem... read more Featured Products: More products

Download Mobile App




Repeatability and Reproducibility of a Handheld Quantitative G6PD Diagnostic

By LabMedica International staff writers
Posted on 03 Mar 2022

Novel treatment regimens for the radical cure of P. More...

vivax malaria are more effective than current options but require prior quantitative G6PD testing. The reference method for quantitative G6PD measurement is spectrophotometry but, due to its operational characteristics, is not suitable for routine use. Furthermore, poor inter-laboratory reproducibility of spectrophotometry has prevented quantitative global definitions of G6PD deficiency. SD Biosensor (ROK) have developed a novel handheld “Biosensor” device (G6PD STANDARD), which measures G6PD activity within two minutes and has operational characteristics suited to point of care diagnosis.

Approximately 400 million people worldwide are affected by glucose-6-phosphate dehydrogenase enzyme deficiency (G6PDd), with allele frequencies reaching up to 35% in malaria endemic areas. The introduction of novel short course treatment regimens for the radical cure of Plasmodium vivax requires reliable point-of-care diagnosis that can identify G6PD deficient individuals.

The G6PD gene is located on the X-chromosome; males are either hemizygous deficient or normal, whereas females are homozygous deficient, normal, or heterozygous for the gene. Heterozygous females have two distinct red blood cell (RBC) populations, G6PD normal and G6PD deficient that circulate in a ratio determined through the random process of lyonization Therefore, the G6PD activity levels of heterozygous females is dependent on the proportion of deficient cells, those cells at greatest risk of drug induced hemolysis.

An international team of medical scientists led by those at the Charles Darwin University (Darwin, Australia) determined the repeatability of a point-of-care assay (precision when repeated under constant conditions) and reproducibility (assay precision under different conditions, such as across devices, operators and sites), since robust performance of these characteristics is necessary for rolling-out universal thresholds for clinical decisions.

A hand-held quantitative G6PD diagnostic developed by SD Biosensor (STANDARD G6PD test, Suwon-si, Republic of Korea), and was tested in the study. The Biosensor device quantifies hemoglobin (Hb) concentration using a photo-reflectance based algorithm informed by the sample’s color intensity. This is measured on a separate spot to that for the G6PD activity. The handheld device displays G6PD activity (in U/gHb) and hemoglobin (Hb) levels (in g/dL) two minutes after applying the blood buffer solution, however the manufacturer indicates that results cannot be considered if Hb readings are equal to or below 7g/dL. To ensure that identical samples were tested across all sites, commercial controls were used with all controls within one phase being from the same lot (Analytical Control Systems, Inc., Fishers, IN; USA). Spectrophotometry was performed using kits from Pointe Scientific (Canton, MI, USA).

The investigators reported that when tested at one site, the mean coefficient of variation (CV) was 0.111, 0.172 and 0.260 for high, intermediate, and low controls across all devices respectively; combined G6PD Biosensor readings correlated well with spectrophotometry (rs = 0.859). When tested in different laboratories, correlation was lower (rs = 0.604) and G6PD activity determined by Biosensor for the low and intermediate controls overlapped. The use of lyophilized human blood samples rather than fresh blood may have affected these findings. Biosensor G6PD readings between sites did not differ significantly, whereas spectrophotometry readings differed markedly between sites.

The authors concluded that their findings suggest that the Biosensor offers reproducible quantitative diagnosis of G6PD status at the point-of-care in the hands of well-trained technicians. If repeatability and reproducibility as well as the previously reported accuracy are confirmed under real life conditions, the Biosensor has the potential to simplify access to effective radical cure of P. vivax malaria. The study was published on February 17, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Charles Darwin University
SD Biosensor 
Analytical Control Systems 
Pointe Scientific 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Clinical Chemistry System
P780
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.